Research Paper Volume 12, Issue 22 pp 23306—23325

Figure 9. Identification of 8-IRlncRNA signature for predicting immunotherapeutic response in BLCA. (A) The relationship between the mismatch repair (MMR) genes and risk score defined by the 8-IRlncRNA signature. (B) The different expressions of MSH6 and MLH1 among risk groups as defined by the 8-IRlncRNA signature. (C) Significant association between our immune-related lncRNA signature and immune checkpoint inhibitors PD-1 and PD-L1. (D) The different expressions of PD-1 and PD-L1 among risk groups as defined by the 8-IRlncRNA signature. (E) The difference of tumor mutation burden (TMB) among risk groups as defined by the 8-IRlncRNA signature. (F) The difference of the risk score in two groups (response vs. non-response to the anti-PD-1 therapy).